Maravai LifeSciences Holdings, Inc.
MRVI
$2.06
$0.052.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 241.86M | 259.19M | 276.92M | 278.59M | 274.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 241.86M | 259.19M | 276.92M | 278.59M | 274.10M |
| Cost of Revenue | 151.67M | 150.88M | 148.54M | 148.40M | 153.40M |
| Gross Profit | 90.19M | 108.31M | 128.38M | 130.19M | 120.70M |
| SG&A Expenses | 160.45M | 161.77M | 154.91M | 154.68M | 149.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 331.19M | 331.87M | 322.70M | 322.34M | 321.07M |
| Operating Income | -89.34M | -72.68M | -45.78M | -43.76M | -46.97M |
| Income Before Tax | -291.76M | -261.48M | 441.21M | 596.29M | 599.85M |
| Income Tax Expenses | -1.97M | -1.86M | 764.32M | 758.54M | 759.56M |
| Earnings from Continuing Operations | -289.80 | -259.62 | -323.11 | -162.26 | -159.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 127.08M | 114.78M | 98.45M | 30.17M | 28.67M |
| Net Income | -162.71M | -144.85M | -224.66M | -132.08M | -131.04M |
| EBIT | -89.34M | -72.68M | -45.78M | -43.76M | -46.97M |
| EBITDA | -39.89M | -24.30M | 1.04M | 2.07M | -3.91M |
| EPS Basic | -1.15 | -1.03 | -1.65 | -1.00 | -0.99 |
| Normalized Basic EPS | 0.40 | 0.39 | 3.55 | 3.08 | 3.08 |
| EPS Diluted | -1.15 | -1.03 | -1.65 | -1.00 | -0.99 |
| Normalized Diluted EPS | 0.40 | 0.39 | 3.55 | 3.08 | 3.08 |
| Average Basic Shares Outstanding | 562.63M | 551.54M | 541.87M | 532.25M | 528.27M |
| Average Diluted Shares Outstanding | 562.63M | 551.54M | 541.87M | 532.25M | 528.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |